These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Active surveillance for the management of prostate cancer in a contemporary cohort. Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013 [TBL] [Abstract][Full Text] [Related]
4. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance. Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065 [TBL] [Abstract][Full Text] [Related]
5. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361 [TBL] [Abstract][Full Text] [Related]
6. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan. Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752 [TBL] [Abstract][Full Text] [Related]
7. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. Krakowsky Y; Loblaw A; Klotz L J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589 [TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Bul M; Zhu X; Rannikko A; Staerman F; Valdagni R; Pickles T; Bangma CH; Roobol MJ Eur Urol; 2012 Aug; 62(2):195-200. PubMed ID: 22342775 [TBL] [Abstract][Full Text] [Related]
9. Early outcomes of active surveillance for localized prostate cancer. Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912 [TBL] [Abstract][Full Text] [Related]
10. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973 [TBL] [Abstract][Full Text] [Related]
12. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Bul M; Zhu X; Valdagni R; Pickles T; Kakehi Y; Rannikko A; Bjartell A; van der Schoot DK; Cornel EB; Conti GN; Boevé ER; Staerman F; Vis-Maters JJ; Vergunst H; Jaspars JJ; Strölin P; van Muilekom E; Schröder FH; Bangma CH; Roobol MJ Eur Urol; 2013 Apr; 63(4):597-603. PubMed ID: 23159452 [TBL] [Abstract][Full Text] [Related]
13. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447 [TBL] [Abstract][Full Text] [Related]
14. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457 [TBL] [Abstract][Full Text] [Related]
15. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria? Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888 [TBL] [Abstract][Full Text] [Related]
16. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068 [TBL] [Abstract][Full Text] [Related]